Clinical Trials and Research1 min read
Cost-Effectiveness of Sickle Cell Transplant vs Gene Therapy
About this article
- Published
- Last updated
- Further reading
- Read More(opens in a new tab)
Summary
Question
This study analyzed the cost-effectiveness of three treatment strategies for sickle cell disease (SCD): standard care (SOC), gene therapy (GT), and non-myeloablative haploidentical allogeneic stem cell transplantation (NMAC-HID allo-HSCT). Researchers aimed to determine which approach offers the best value in terms of quality-adjusted life years (QALYs)—a measure combining life expectancy and quality of life—across diverse healthcare systems, including the United States and several low- and middle-income countries.